Cases & Deals

BioMarin develops gene therapy treatment for PKU

Clients BioMarin Pharmaceutical Inc.

Jones Day is representing BioMarin Pharmaceutical Inc. in its development of a phenylalanine hydroxylase ("PAH") gene therapy treatment for phenylketonuria ("PKU").